Cross-Protection against H5N1 Infection by Intranasal Seasonal Vaccine

[Niko]

Cross-Protection against H5N1 Influenza Virus Infection Is Afforded by Intranasal Inoculation with Seasonal Trivalent Inactivated Influenza Vaccine

<table border="0" cellpadding="0" cellspacing="0" width="450"> <tbody> <tr><td class="contentAuthor"><author><fname>Takeshi </fname><surname>Ichinohe</surname></author>, <author><fname>Shin-ichi </fname><surname>Tamura</surname></author>, <author><fname>Akira </fname><surname>Kawaguchi</surname></author>, <author><fname>Ai </fname><surname>Ninomiya</surname></author>, <author><fname>Masaki </fname><surname>Imai</surname></author>, <author><fname>Shigeyuki </fname><surname>Itamura</surname></author>, <author><fname>Takato </fname><surname>Odagiri</surname></author>, <author><fname>Masato </fname><surname>Tashiro</surname></author>, <author><fname>Hidehiro </fname><surname>Takahashi</surname></author>, <author><fname>Hirofumi </fname><surname>Sawa</surname></author>, <author><fname>William M. </fname><surname>Mitchell</surname></author>, <author><fname>David R. </fname><surname>Strayer</surname></author>, <author><fname>William A. </fname><surname>Carter</surname></author>, <author><fname>Joe </fname><surname>Chiba</surname></author>, <author><fname>Takeshi </fname><surname>Kurata</surname></author>, <author><fname>Tetsutaro </fname><surname>Sata</surname></author>, and <author><fname>Hideki </fname><surname>Hasegawa</surname></author></td></tr> <tr><td>
</td></tr> <tr><td>Volume 196(2007), pages 1313 - 1320
DOI: 10.1086/521304

</td></tr> </tbody> </table> <table border="0" cellpadding="0" cellspacing="0"><tbody><tr><td>Abstract

</td></tr> <tr><td>Background. Avian H5N1 influenza A virus is an emerging pathogen with the potential to cause substantial human morbidity and mortality. We evaluated the ability of currently licensed seasonal influenza vaccine to confer cross-protection against highly pathogenic H5N1 influenza virus in mice.

Methods. BALB/c mice were inoculated 3 times, either intranasally or subcutaneously, with the trivalent inactivated influenza vaccine licensed in Japan for the 2005

2006 season. The vaccine included A/NewCaledonia/20/99 (H1N1), A/NewYork/55/2004 (H3N2), and B/Shanghai/361/2002 viral strains and was administered together with poly(I)oly(C<tinf>12</tinf>U) (Ampligen) as an adjuvant. At 14 days after the final inoculation, the inoculated mice were challenged with either the A/HongKong/483/97, the A/Vietnam/1194/04, or the A/Indonesia/6/05 strain of H5N1 influenza virus.

Results. Compared with noninoculated mice, those inoculated intranasally manifested cross-reactivity of mucosal IgA and serum IgG with H5N1 virus, as well as both a reduced H5N1 virus titer in nasal-wash samples and increased survival, after challenge with H5N1 virus. Subcutaneous inoculation did not induce a cross-reactive IgA response and did not afford protection against H5N1 viral infection.

Conclusions. Intranasal inoculation with annual influenza vaccine plus the Toll-like receptor

3 agonist, poly(I)oly(C<tinf>12</tinf>U), may overcome the problem of a limited supply of H5N1 virus vaccine by providing cross-protective mucosal immunity against H5N1 viruses with pandemic potential.

</td></tr> <tr><td>

http://www.journals.uchicago.edu/uc...5884672617836740132Guest&current_page=content

</td></tr></tbody></table>

 

[gsgs]

Re: Cross-Protection against H5N1 Infection by Intranasal Seasonal Vaccine

OK, so the vaccine was "somehow" protective in mice".
To figure out, how much you have to subscribe or register.
So, that info is presumably copyright and mustn't be talked about ?

How much does vaccination against seasonal flu increase
my chance to survive panflu ?
The authors won't tell us their estimate, so I'll have to make my
own estimate without that info.
0.1% probability that I'll die next year due to panflu
reduced to 0.09% by seasonal vaccination.
probability to die from the vaccination 0.003%.
Probability to die from seasonal flu next year:0.01%
reduced to 0.008% by vaccination

 

[Niko]

Re: Cross-Protection against H5N1 Infection by Intranasal Seasonal Vaccine

OK, so the vaccine was "somehow" protective in mice".
To figure out, how much you have to subscribe or register.
So, that info is presumably copyright and mustn't be talked about ?

How much does vaccination against seasonal flu increase
my chance to survive panflu ?
The authors won't tell us their estimate, so I'll have to make my
own estimate without that info.
0.1% probability that I'll die next year due to panflu
reduced to 0.09% by seasonal vaccination.
probability to die from the vaccination 0.003%.
Probability to die from seasonal flu next year:0.01%
reduced to 0.008% by vaccination

If I had a subscription, I would have posted the entire paper (or pertainent info, at least). Maybe someone else with access would be willing to post it for discussion.

 

[Anne]

Re: Cross-Protection against H5N1 Infection by Intranasal Seasonal Vaccine

http://www.cdc.gov/eid/content/14/1/121.htm




Research

Cross-subtype Immunity against Avian Influenza in Persons Recently Vaccinated for Influenza

Cristiana Gioia,* Concetta Castilletti,* Massimo Tempestilli,* Paola Piacentini,* Licia Bordi,* Roberta Chiappini,* Chiara Agrati,* Salvatore Squarcione,* Giuseppe Ippolito,* Vincenzo Puro,* Maria R. Capobianchi,* and Fabrizio Poccia*
*National Institute for Infectious Diseases "Lazzaro Spallanzani," Rome, Italy
Suggested citation for this article
Abstract
Avian influenza virus (H5N1) can be transmitted to humans, resulting in a severe or fatal disease. The aim of this study was to evaluate the immune cross-reactivity between human and avian influenza (H5N1) strains in healthy donors vaccinated for seasonal influenza A (H1N1)/(H3N2). A small frequency of CD4 T cells specific for subtype H5N1 was detected in several persons at baseline, and seasonal vaccine administration enhanced the frequency of such reactive CD4 T cells. We also observed that seasonal vaccination is able to raise neutralizing immunity against influenza (H5N1) in a large number of donors. No correlation between influenza-specific CD4 T cells and humoral responses was observed. N1 may possibly be a target for both cellular and humoral cross-type immunity, but additional experiments are needed to clarify this point. These findings highlight the possibility of boosting cross-type cellular and humoral immunity against highly pathogenic avian influenza A virus subtype H5N1 by seasonal influenza vaccination.